Search

Your search keyword '"Tytgat, Godelieve A M"' showing total 4 results
Start Over Author "Tytgat, Godelieve A M" Journal frontiers in oncology
4 results on '"Tytgat, Godelieve A M"'

1. Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors

Author

van Zogchel, Lieke M. J., primary, Lak, Nathalie S. M., additional, Gelineau, Nina U., additional, Sergeeva, Irina, additional, Stelloo, Ellen, additional, Swennenhuis, Joost, additional, Feitsma, Harma, additional, van Min, Max, additional, Splinter, Erik, additional, Bleijs, Margit, additional, Groot Koerkamp, Marian, additional, Breunis, Willemijn, additional, Meister, Michael Torsten, additional, Kholossy, Waleed Hassan, additional, Holstege, Frank C. P., additional, Molenaar, Jan J., additional, de Leng, Wendy W. J., additional, Stutterheim, Janine, additional, van der Schoot, C. Ellen, additional, and Tytgat, Godelieve A. M., additional

Published
2023
Full Text
View/download PDF

2. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Author

Eleveld, Thomas F., primary, Vernooij, Lindy, additional, Schild, Linda, additional, Koopmans, Bianca, additional, Alles, Lindy K., additional, Ebus, Marli E., additional, Dandis, Rana, additional, van Tinteren, Harm, additional, Caron, Huib N., additional, Koster, Jan, additional, van Noesel, Max M., additional, Tytgat, Godelieve A. M., additional, Eising, Selma, additional, Versteeg, Rogier, additional, Dolman, M. Emmy M., additional, and Molenaar, Jan J., additional

Published
2023
Full Text
View/download PDF

4. Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.

Author

Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, den Handel, Kim van, den Boogaard, Marlinde van, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A. M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., and van Hooff, Sander R.

Subjects
NEUROBLASTOMA, CHECKPOINT kinase 1, CHROMOSOMES, CHROMOSOME abnormalities, TUMORS in children, HIGH throughput screening (Drug development)
Abstract

Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of chromosome 11q and MYCN amplification are two genetically distinct subsets of neuroblastoma that are associated with poor patient outcome. Using an isogenic 11q deleted model system and high-throughput drug screening, we identify checkpoint kinase 1 (CHK1) as a potential therapeutic target for 11q deleted neuroblastoma. Further investigation reveals MYCN amplification as a possible additional biomarker for CHK1 inhibition, independent of 11q loss. Overall, our study highlights the potential power of studying chromosomal aberrations to guide preclinical development of novel drug targets and combinations. Additionally, our study builds on the growing evidence that DNA damage repair and replication stress response pathways offer therapeutic vulnerabilities for the treatment of neuroblastoma. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results